Following FDA's PAT initiative, it is imperative that critical process parameters (CPP) that significantly impact critical quality attributes (CQA's) of a process are monitored and controlled strictly. It is also well known that viable biomass is one such CPP, or even a Key Performance Indicator, which can impact CQA's in a biopharmaceutical process. Dielectric spectroscopy, often referred to as capacitance measurement, has been used for monitoring live biomass in bioprocesses in real time routinely over the past two decades. This technology has been used in the industry for applications ranging from batch fingerprinting, troubleshooting, optimization of nutrient feed, viral infection, cell density control, scale up, among others. Over the past few years, the field of regenerative medicine is increasingly gaining attention. Owing to its success in various bioprocess applications, dielectric spectroscopy has also been evaluated for processes involving regenerative medicine and monitoring cell density in 3D tissues.
As a joint initiative between ARMI, NCSU and Aber Instruments, this webinar will cover the principle of dielectric spectroscopy to measure cell density in bioprocesses. It will also highlight how the technology has been used in the bioprocess industry over the past three decades. As importantly, it will talk about its recent use to measure cell density non-disruptively in 3D tissues in real time. Owing to the challenges of measuring cell density on this platform, dielectric spectroscopy offers a unique advantage of doing so in real time, reliably without disrupting the tissue. Thus, it holds promise in potentially providing a crucial quality parameter when working with such platforms and processes.